The 43 gene cancer panel consisted of significantly mutated genes from the TCGA and ACRG cohort [6, 28, 40], genes associated with new targeted therapy of GC (EGFR, ERBB2, FGFR2, and KDR) and hereditary cancer syndromes (CDH1, MSH2, MLH1, STK11, and TP53) [12]. The gene discussed is FGFR2; the disease is Inherited cancer-predisposing syndrome.